ABSTRACT
No disponible
Subject(s)
Humans , Adult , Biological Treatment/methods , Etanercept/therapeutic use , Adalimumab/therapeutic use , Ustekinumab/therapeutic use , Treatment Outcome , Retrospective StudiesSubject(s)
Adalimumab/therapeutic use , Dermatologic Agents/therapeutic use , Etanercept/therapeutic use , Psoriasis/drug therapy , Psoriasis/pathology , Severity of Illness Index , Ustekinumab/therapeutic use , Adalimumab/adverse effects , Adult , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/therapeutic use , Body Weight , Dermatologic Agents/adverse effects , Female , Humans , Male , Middle Aged , Retrospective Studies , Time Factors , Treatment Outcome , Ustekinumab/adverse effectsABSTRACT
Antecedentes y objetivo: Los ensayos pivotales de omalizumab en urticaria crónica espontánea (UCE) tienen un periodo de tratamiento de entre 12 y 24 semanas. Sin embargo, muchos pacientes en práctica clínica requieren periodos de tratamiento más prolongados. Por ello el objetivo es presentar un algoritmo de manejo del fármaco. Materiales y métodos: El documento de consenso que detallamos nace de la puesta en común, aceptación, revisión y confrontación de la literatura reciente del grupo de trabajo de UCE "Xarxa d'Urticària Catalana i Balear" (XUrCB). Resultados: Se inicia el tratamiento a dosis autorizada y se ajusta la dosis en intervalos trimestrales en función del Urticaria Activity Score de los últimos 7 días (UAS7) y/o el Urticarial Control Test (UCT). Conclusiones: El algoritmo propuesto pretende servir de guía respecto a cómo ajustar dosis, cómo y cuándo parar el fármaco y el modo de reintroducirlo en casos de recaída
Background and objective: Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with omalizumab. Material and methods: The consensus document we present is the result of a series of meetings by the CSU working group of "Xarxa d'Urticària Catalana i Balear" (XUrCB) at which data from the recent literature were presented, discussed, compared, and agreed upon. Results: Treatment with omalizumab should be initiated at the authorized dose, and is adjusted at 3-monthly intervals according to the Urticaria Activity Score Over 7 days, the Urticaria Control Test, or both. Conclusions: The algorithm proposed is designed to provide guidance on how to adjust omalizumab doses, how and when to discontinue the drug, and how to reintroduce it in cases of relapse
Subject(s)
Humans , Urticaria/drug therapy , Omalizumab/administration & dosage , Algorithms , Consensus , Dosage/methods , Histamine H1 Antagonists/administration & dosage , Dose-Response Relationship, DrugABSTRACT
BACKGROUND AND OBJECTIVE: Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with omalizumab. MATERIAL AND METHODS: The consensus document we present is the result of a series of meetings by the CSU working group of "Xarxa d'Urticària Catalana i Balear" (XUrCB) at which data from the recent literature were presented, discussed, compared, and agreed upon. RESULTS: Treatment with omalizumab should be initiated at the authorized dose, and is adjusted at 3-monthly intervals according to the Urticaria Activity Score Over 7days, the Urticaria Control Test, or both. CONCLUSIONS: The algorithm proposed is designed to provide guidance on how to adjust omalizumab doses, how and when to discontinue the drug, and how to reintroduce it in cases of relapse.
Subject(s)
Algorithms , Anti-Allergic Agents/therapeutic use , Omalizumab/therapeutic use , Urticaria/drug therapy , Anti-Allergic Agents/administration & dosage , Chronic Disease , Humans , Omalizumab/administration & dosageSubject(s)
Anti-Allergic Agents/administration & dosage , Chronic Disease/drug therapy , Omalizumab/administration & dosage , Urticaria/drug therapy , Adult , Age Factors , Dose-Response Relationship, Drug , Drug Resistance , Female , Humans , Middle Aged , Retrospective Studies , Treatment Outcome , Urticaria/pathologyABSTRACT
No disponible
Subject(s)
Humans , Erythema/etiology , Facial Dermatoses/etiology , Flushing/diagnosis , Alcohol Drinking/physiopathology , Biomarkers/analysis , Brimonidine Tartrate/therapeutic use , Diagnosis, Differential , Emotions , Endocrine System DiseasesABSTRACT
No disponible
